Timothy Powell, MD
Epilepsy · Spokane, WANPI 1982697090
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,500 of the $2,280 with a category attached, or 65.8%. Livanova USA, Inc. accounts for 88.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $1,513 and has fallen 90.1% since, to $150 in 2025.
Across 36 payments — averaging $63.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- Amneal Pharmaceuticals LLC$62
- Teva Pharmaceuticals USA, Inc.$51
- UCB, Inc.$39
- Neurelis, Inc.$26
- Pfizer$24
- plus $69 from 4 others
What the payments were for
- Speaking & faculty fees$1,50066%
- Food & beverage$65529%
- Education$1255%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 23 | $2,010 |
| Amneal Pharmaceuticals LLC | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 1 | $51 |
| UCB, Inc. | 2 | $39 |
| Neurelis, Inc. | 2 | $26 |
| Pfizer | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| SK Life Science, Inc. | 1 | $19 |
| Greenwich Biosciences, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS - Sentiva$1,500
- VNS Therapy$112
How this compares
Too few epilepsy providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LamictalLamotrigine | 95 | $110,484 |
| EpidiolexCannabidiol (Cbd) | 23 | $108,527 |
| ZonegranZonisamide | 22 | $91,292 |
| TopamaxTopiramate | 67 | $78,969 |
| KeppraLevetiracetam | 34 | $73,016 |
| FycompaPerampanel | 34 | $71,709 |
| FelbatolFelbamate | 29 | $57,132 |
| Topiramate ErTopiramate | 42 | $55,935 |
| BriviactBrivaracetam | 24 | $48,941 |
| XcopriCenobamate | 36 | $47,821 |
| TrileptalOxcarbazepine | 22 | $43,754 |
| Lamotrigine ErLamotrigine | 136 | $39,930 |
| Keppra XrLevetiracetam | 19 | $38,892 |
| DepakoteDivalproex Sodium | 41 | $31,084 |
| Lamotrigine | 1,141 | $29,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat | $39 | $65,82438 claims |
| SK Life Science, Inc.Xcopri | $19 | $47,82136 claims |
| Neurelis, Inc.Valtoco | $26 | $16,48221 claims |
| PfizerDilantin | $24 | $6,63544 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in Washingtonon file to place this against a meaningful peer group, so we don't.
Other epilepsy in Spokane
- Natasha SparrowSpokane$1K
- Thomas BullockBellevue$8K
- Nicholas PoolosSeattle$3K
- John EatonBellevue$2K
- Wolfgang MuhlhoferSeattle$940
- Nausheen MahmoodSeattle$769
- Noah EbySeattle$500
- Shahin HakimianSeattle$486
- Denise ChenSeattle$22
- Behnaz EsmaeiliSeattle$13
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.